文献速递重症综合管理与镇静镇痛

褪黑素预防ICU机械通气患者谵妄:多臂多阶段适应性随机对照临床试验(DEMEL)

Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit: a multiarm multistage adaptive randomized controlled clinical trial (DEMEL).
PubMed 文献 · Intensive Care Med · 2025-07-03
一句话结论低剂量褪黑素(0.3 mg每晚)药代动力学特征优于高剂量(3 mg每晚),但与安慰剂相比未降低机械通气ICU患者的谵妄发生率(54.4% vs 55.2%,RR 0.986)。

DEMEL是一项在法国20个中心开展的多中心适应性2b/3期随机、安慰剂对照、双盲试验,纳入355例机械通气ICU患者,随机分配至安慰剂组、低剂量褪黑素(0.3 mg)组或高剂量褪黑素(3 mg)组,每晚9点经肠内给药,连续14晚或直至死亡或ICU出院。活动期预设分析(75例)显示低剂量组最佳药代动力学特征比例最高(12/24,50%),高于高剂量组(6/25,24%)和安慰剂组(0/26), steering committee建议停用高剂量组,低剂量组与安慰剂组继续进入疗效期。疗效期最终主要终点显示低剂量褪黑素组与安慰剂组谵妄发生率无差异:80/147(54.4%)vs 85/154(55.2%),RR 0.986(95%CI 0.803-1.211);关键次要终点(睡眠质量、无谵妄、无昏迷、无机械通气天数、ICU及住院时间、28天、ICU及住院死亡率、90天生活质量和重症后综合征)两组也相似。

要点

  • 低剂量褪黑素(0.3 mg每晚)药代动力学特征优于高剂量(3 mg每晚):最佳药代动力学特征比例低剂量组50%(12/24)vs 高剂量组24%(6/25)vs 安慰剂组0%(0/26)。
  • 低剂量褪黑素未降低谵妄发生率:低剂量组80/147(54.4%)vs 安慰剂组85/154(55.2%),RR 0.986(95%CI 0.803-1.211)。
  • 关键次要终点(睡眠质量、无谵妄、无昏迷、无机械通气天数、ICU及住院时间、28天、ICU及住院死亡率、90天生活质量和重症后综合征)两组相似。
  • 给药方式为每晚9点经肠内给予褪黑素,连续14晚或直至死亡或ICU出院,以先发生者为准。
  • 谵妄评估使用ICU意识模糊评估法(CAM-ICU),每日两次。

适用人群与场景

  • 法国20个健康中心收治的机械通气ICU患者,纳入时间2019年2月1日至2021年1月5日。

诊断标准与关键阈值

  • 谵妄评估采用ICU意识模糊评估法(CAM-ICU),每日两次。

处置流程与药物剂量

  • 随机分配(1:1:1)至安慰剂组、低剂量褪黑素(0.3 mg)组或高剂量褪黑素(3 mg)组,每晚9点经肠内给药,连续14晚或直至死亡或ICU出院,以先发生者为准。
  • 活动期预设分析(75例)后,指导委员会建议停用高剂量褪黑素组,低剂量褪黑素组与安慰剂组继续进入疗效期。

研究设计与关键结果

  • 多中心适应性2b/3期随机、安慰剂对照、双盲试验,随机355例,主要分析纳入334例。
  • 活动期预设分析(75例):最佳药代动力学特征比例低剂量褪黑素组12/24(50%)vs 高剂量褪黑素组6/25(24%)vs 安慰剂组0/26(0%)。
  • 疗效期最终主要终点:谵妄发生率低剂量褪黑素组80/147(54.4%)vs 安慰剂组85/154(55.2%),RR 0.986(95%CI 0.803-1.211)。
  • 关键次要终点(睡眠质量、无谵妄、无昏迷、无机械通气天数、ICU及住院时间、28天、ICU及住院死亡率、90天生活质量和重症后综合征)两组相似。

证据类型、等级与局限

  • 证据类型:多中心适应性2b/3期随机、安慰剂对照、双盲临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:低剂量褪黑素(0.3 mg每晚)药代动力学特征优于高剂量(3 mg每晚),但与安慰剂相比未改变机械通气危重患者的谵妄发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To determine the dose of melatonin with an optimal pharmacokinetic profile and to test whether this dose reduces the prevalence of delirium in mechanically ventilated ICU patients as compared to placebo.

METHODS: DEMEL, a multicenter adaptive phase 2b/3 randomized, placebo-controlled, double-blind trial included patients at 20 health centers in France from February 1st, 2019 through January 5th, 2021. Patients were randomized (1:1:1) to receive either placebo or low (0.3 mg) or high (3 mg) dose melatonin enterally at 9:00 p.m. for 14 consecutive nights or until death or ICU discharge, whichever came first. The interim primary endpoint (activity stage) was the percentage of patients who achieved an optimal melatonin pharmacokinetic profile 24 h after starting study treatment; the final primary endpoint (efficacy phase) was the percentage of patients who experienced delirium between randomization and day 14 (or until death or ICU discharge, whichever came first). Delirium was assessed twice daily using the Confusion Assessment Method for ICU.

RESULTS: We randomized 355 patients and included 334 in the primary analysis. At the preplanned analysis of the activity stage performed in 75 patients, the low-dose melatonin group had the highest rate of optimal pharmacokinetic profiles (12/24, 50%) when compared with the high-dose melatonin group (6/25, 24%) and the placebo group (0/26). Therefore, the Steering Committee recommended that the high-dose melatonin group be discontinued and that the low-dose melatonin group be selected to continue in the efficacy phase along with the placebo group. At the end of the efficacy stage, there was no difference in the final primary outcome of delirium incidence between the low-dose melatonin group and the placebo group: 80/147 (54.4%) vs 85/154 (55.2%), risk ratio, 0.986 [95% CI 0.803 to 1.211]; key secondary outcomes were also similar between groups. These included sleep quality, delirium-free, coma-free, and ventilator-free days at day 28; ICU and hospital length of stay; mortality at day 28, in the ICU, and in hospital; as well as long-term outcomes such as quality of life and postintensive care syndrome at day 90.

CONCLUSIONS: This randomized clinical trial found that the low-dose of melatonin (0.3 mg nightly) achieved a better pharmacokinetic profile than the high-dose (3 mg nightly), but did not change the incidence of delirium compared to placebo in mechanically ventilated critically-ill patients.

TRIAL REGISTRATION: ClinicalTrial.gov website (NCT03524937).

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mekontso Dessap A, Ricard JD, Contou D, et al. Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit: a multiarm multistage adaptive randomized controlled clinical trial (DEMEL). Intensive Care Med. 2025. PMID: 40608082. doi:10.1007/s00134-025-08002-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。